BMO Capital Lowers Pfizer Price Target to $30, Maintains Outperform Rating

Key Facts

Amid a broader recalibration within the major pharmaceutical sector, BMO Capital has adjusted its price target for Pfizer (PFE) to $30 from $34. Despite the reduction, analysts maintained an 'Outperform' rating on the stock, signaling continued confidence in the company's long-term trajectory. This adjustment follows a series of analyst revisions and recent FDA approvals for co-developed drugs, reflecting a valuation shift despite a positive fundamental outlook.

The move by BMO Capital comes as the healthcare sector navigates mixed pressures, with market data showing a downward trend in valuations for several industry giants compared to previous quarters. Per market data, peers such as Johnson & Johnson and Merck have faced similar price target adjustments as the market adjusts to post-pandemic dynamics. Industry experts suggest that Pfizer's strategic focus on acquisitions and pipeline development remains a critical factor in supporting its investment thesis despite the lowered target.

Regarding price action, PFE stood at $24.17 (close July 10, 2026), leaving significant upside potential relative to the new $30 target. Traders are monitoring support levels near the recent daily low of $24.10. Looking ahead, the market will be watching upcoming US economic data, including the ISM Services PMI, which could influence broader market sentiment and the performance of defensive stocks in the pharmaceutical space.